Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761282 | 0.91 | SYK (0.66) | SYKJAK3IRAK4ROCK2ROCK1 | |
| SCHEMBL6639550 | 0.90 | SYK (0.53) | SYKJAK3IRAK4MKNK1ROCK2 | |
| SCHEMBL6769085 | 0.88 | SYK (0.52) | SYKIRAK4MKNK1ROCK2ROCK1 | |
| SCHEMBL6769846 | 0.87 | MKNK1 (0.55) | SYKMKNK1ROCK2ROCK1EGFR | |
| SCHEMBL6611762 | 0.85 | SYK (0.49) | SYKMKNK1ROCK2ROCK1EGFR | |
| SCHEMBL6644053 | 0.85 | SYK (0.67) | SYKJAK3EGFR | |
| SCHEMBL6770452 | 0.84 | RPS6KB1 (0.51) | SYKJAK3IRAK4MKNK1ROCK2 | |
| SCHEMBL10241915 | 0.83 | SYK (0.73) | SYKJAK3IRAK4EGFR | |
| SCHEMBL10242654 | 0.83 | SYK (0.73) | SYKJAK3IRAK4EGFR | |
| SCHEMBL6770721 | 0.82 | PDGFRB (0.53) | SYKJAK3MKNK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2013078468-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-6762189-B1 | HEPATITIS B VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS ANTIPROLIFERATION AGENTS; REDUCED CHANCE OF TOXICITY, SIDE EFFECTS, AND DEVELOPMENT OF RESISTANT VIRAL STRAINS | DONG WHA PHARM. IND. CO., LTD. (KR) | 2004-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | SYK, BTK, LCK | SYK 1/4885JAK3 121/4885IRAK4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.